Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide and Niclosamide in Castration-Resistant Prostate Cancer
NCT03123978Phase 1Completed
- Sponsor
- University of California, Davis
- Start
- Jan 2017
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of niclosamide in castration-resistant prostate cancer (CRPC), sponsored by University of California, Davis. Primary endpoints: Incidence of adverse events of grade 3 or higher up to 4 weeks and Recommended phase II dose up to 2 years. Started Jan 2017; status: completed.
02
Drugs
niclosamide
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT03123978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03123978.